Back to Blog

How a leading biotechnology company partnered with InfinixBio to engineer and deliver usable strains for their line of custom therapeutic antibodies.

Just over 10 years ago, a company focused on product development in the genetic engineering space approached our team with a problem: their efforts to develop a complete platform strain required scientific resources that would have otherwise been devoted to protein development.

In addition to being time-consuming and unpredictable, the process was hindering their previously established production goals. The company wanted InfinixBio’s expert assistance engineering production cell lines for therapeutic protein development.

Leveraging extensive genetic engineering and cell biology expertise, as well as advanced knowledge of Lambda Red recombineering-based chromosomal engineering, CRISPR-mediated genome editing, and synthetic DNA design versatility, we began working toward optimizing our client’s production cell lines.

Throughout the early stages of the strain development and optimization process, there were numerous challenges related to cell growth and stability, protein production levels, and unexpected engineering results.

Our team quickly and efficiently worked through these issues to develop value-driven therapeutic protein development production cell lines.